Your browser doesn't support javascript.
loading
Children and adolescents with non-Hodgkin lymphoma in Brazil: A national survey identifies the challenges encountered and documents the diversity of care
Costa, Ana Rosa S; Costa, Juliana T; Breviglieri, Carla Nolasco Monteiro; Melgares, Lucélia M. P; Godinho, Patrick R; Metzger, Monika L.
Afiliação
  • Costa, Ana Rosa S; Universidade Estadual Paulista (UNESP). Faculdade de Medicina de Botucatu. Botucatu. BR
  • Costa, Juliana T; Hospital Martagão Gesteira. Salvador. BR
  • Breviglieri, Carla Nolasco Monteiro; Hospital Samaritano Higienópolis. São Paulo. BR
  • Melgares, Lucélia M. P; Hospital da Criança José de Alencar. Brasília. BR
  • Godinho, Patrick R; Fundação Pio-XII. Hospital de Amor da Amazônia. Porto Velho. BR
  • Metzger, Monika L; St Jude Childrens Research Hospital. Memphis. US
Hematol., Transfus. Cell Ther. (Impr.) ; 45(supl.2): S36-S42, July 2023. tab, graf
Article em En | LILACS | ID: biblio-1514185
Biblioteca responsável: BR408.1
Localização: BR408.1
ABSTRACT
ABSTRACT

Introduction:

Brazil has many inequities in the healthcare provided nationwide. Therefore, in order to access challenges in treatment, available resources and current practices, to identify barriers in delivering a good quality of care among Brazilian centers treating children and adolescents with Non-Hodgkin Lymphoma (NHL) and to generate a future prospective guideline, a customized online survey was distributed to pediatric hematologists and oncologists across the country.

Results:

A total of 97 surveys were completed (35% response rate), from 47 cities in all Brazilian regions and 79 units of care, with a median of 1 answer by the center (range 1 - 5). Most respondents work at an institution supported exclusively by public/philanthropic resources (58%), with an average of 5 to 9 new cases/year (49%), and 41% have 4 to 6 oncologists/centers. Additionally, 22% have no easy access to the intensive care unit, 26% have no access to Rasburicase, 28% have no access to Rituximabe as front-line therapy and 41% have unreliable methotrexate monitoring levels. Those differences cannot be explained thoroughly by regional wealth variances, nor by the financing model. Regarding the pathology service, 70% consider having reasonable quality assistance, but the timeframe to deliver diagnosis is satisfactory to 46%. There is no uniform management of care, with the current guideline from the Sociedade Brasileira de Oncologia Pediátrica being adopted by 54 to 59%, depending on the NHL subtype.

Conclusion:

This study provides insights into the heterogeneity of care among Brazilian centers. Recognizing those diversities will support the design of effective strategies and collaboration nationwide.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Linfoma não Hodgkin País/Região como assunto: America do sul / Brasil Idioma: En Revista: Hematol., Transfus. Cell Ther. (Impr.) Assunto da revista: Hematologia / TransfusÆo de Sangue Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil / Estados Unidos País de publicação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Linfoma não Hodgkin País/Região como assunto: America do sul / Brasil Idioma: En Revista: Hematol., Transfus. Cell Ther. (Impr.) Assunto da revista: Hematologia / TransfusÆo de Sangue Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil / Estados Unidos País de publicação: Brasil